X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
regorafenib (568) 568
index medicus (272) 272
oncology (267) 267
humans (215) 215
colorectal cancer (185) 185
sorafenib (146) 146
multicenter (120) 120
chemotherapy (117) 117
cancer (109) 109
metastasis (105) 105
pharmacology & pharmacy (94) 94
hepatocellular carcinoma (89) 89
male (89) 89
colorectal neoplasms - drug therapy (84) 84
female (83) 83
phenylurea compounds - therapeutic use (83) 83
double-blind (80) 80
pyridines - therapeutic use (78) 78
bevacizumab (77) 77
antineoplastic agents - therapeutic use (76) 76
metastatic colorectal cancer (75) 75
tumors (73) 73
middle aged (72) 72
sunitinib (72) 72
cancer therapies (69) 69
drug therapy (69) 69
patients (68) 68
angiogenesis (66) 66
aged (65) 65
safety (62) 62
care and treatment (60) 60
survival (60) 60
medicine & public health (59) 59
phenylurea compounds - adverse effects (58) 58
colorectal neoplasms - pathology (57) 57
pyridines - adverse effects (57) 57
analysis (56) 56
efficacy (56) 56
therapy (56) 56
treatment outcome (56) 56
phase-3 trial (54) 54
liver cancer (53) 53
adult (51) 51
phenylurea compounds - pharmacology (51) 51
animals (50) 50
antineoplastic agents - adverse effects (50) 50
bay 73-4506 (50) 50
clinical trials (49) 49
pyridines - pharmacology (49) 49
imatinib (48) 48
phenylurea compounds - administration & dosage (48) 48
antineoplastic agents - pharmacology (46) 46
pyridines - administration & dosage (46) 46
1st-line treatment (43) 43
placebo (41) 41
colorectal-cancer (40) 40
review (40) 40
protein kinase inhibitors - therapeutic use (39) 39
research (39) 39
gist (38) 38
apoptosis (37) 37
aflibercept (36) 36
cetuximab (36) 36
gastroenterology & hepatology (36) 36
kinases (36) 36
medical prognosis (36) 36
neoplasm metastasis (36) 36
trial (36) 36
vascular endothelial growth factor (36) 36
antineoplastic agents (35) 35
digestive system diseases (35) 35
endothelial growth-factor (35) 35
renal-cell carcinoma (35) 35
antimitotic agents (34) 34
mutation (34) 34
neoplasms. tumors. oncology. including cancer and carcinogens (34) 34
open-label (34) 34
prognosis (33) 33
resistance (33) 33
tyrosine kinase inhibitor (33) 33
tyrosine (32) 32
antineoplastic agents - administration & dosage (31) 31
hypertension (31) 31
inhibitor (31) 31
liver neoplasms - drug therapy (31) 31
tas-102 (30) 30
disease-free survival (29) 29
gastrointestinal stromal tumors (29) 29
antineoplastic combined chemotherapy protocols - therapeutic use (28) 28
health aspects (28) 28
phase-iii (28) 28
protein kinase inhibitors - adverse effects (28) 28
cancer research (27) 27
cell biology (27) 27
development and progression (27) 27
growth (27) 27
metastases (27) 27
molecular targeted therapy (27) 27
niacinamide - analogs & derivatives (27) 27
protein kinase inhibitors - pharmacology (27) 27
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (567) 567
French (8) 8
German (4) 4
Japanese (4) 4
Spanish (4) 4
Korean (3) 3
Czech (2) 2
Chinese (1) 1
Italian (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 4, pp. 350 - 358
Purpose Trifluridine/tipiracil (TAS-102) was effective in patients with metastatic colorectal cancer (mCRC) in a phase II Japanese trial. This regional trial... 
EFFICACY | ONCOLOGY | SAFETY | REGORAFENIB | GUIDELINES | COLON | CLINICAL-PRACTICE
Journal Article
Chinese Journal of New Drugs, ISSN 1003-3734, 10/2018, Volume 27, Issue 20, pp. 2451 - 2457
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 10/2018, Volume 61, Issue 19, pp. 8797 - 8810
While the treatment of gastrointestinal stromal tumors (GISTs) has been revolutionized by the application of targeted tyrosine kinase inhibitors capable of... 
CHEMISTRY, MEDICINAL | IMATINIB | REGORAFENIB | HIGH-AFFINITY | SUNITINIB | MUTATIONS | SHOW | SELECTION
Journal Article
Medicina Clinica, ISSN 0025-7753, 05/2018, Volume 150, Issue 10, pp. 390 - 397
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide with over 740,000 new cases per year and the third leading cause of cancer-related... 
Liver transplant | Regorafenib | Hepatocellular carcinoma | Radioembolization | Sorafenib
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 10/2019, Volume 569, p. 118588
The purpose of this study was to investigate the feasibility of an intravenously administered combinational therapy using lipid nanocapsules (LNCs) as a drug... 
Regorafenib | Lipid nanocapsules | SN38 | Colorectal cancer
Journal Article
Gan to kagaku ryoho. Cancer & chemotherapy, ISSN 0385-0684, 06/2016, Volume 43, Issue 6, pp. 757 - 759
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 10/2019, Volume 85, Issue 10, pp. 2399 - 2404
Aims We investigated whether major gastrectomy influences the plasma exposure of regorafenib and treatment outcome. Methods Efficacy and pharmacokinetic data... 
pharmacokinetics | gastrectomy | regorafenib | gastrointestinal stromal tumour
Journal Article
Oncologist, ISSN 1083-7159, 2019
Regorafenib is a multikinase inhibitor with antiangiogenic effects that improves overall survival (OS) in metastatic colorectal cancer (mCRC) after failure of... 
Regorafenib | Angiogenesis inhibitors | Colorectal neoplasms | Computed tomography | Positron emission tomography
Journal Article
Journal of Pharmaceutical Sciences, ISSN 0022-3549, 06/2019, Volume 108, Issue 6, pp. 2173 - 2179
Journal Article
Recent Results in Cancer Research, ISSN 0080-0015, 2018, Volume 211, pp. 45 - 56
Regorafenib (BAY 73-4506, Stivarga ) is an oral diphenylurea multi-kinase inhibitor that targets angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and... 
Regorafenib | HCC | GIST | TKI | CRC
Journal Article
Gan to kagaku ryoho. Cancer & chemotherapy, ISSN 0385-0684, 11/2014, Volume 41, Issue 12, pp. 1841 - 1843
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2013, Volume 49, Issue 16, pp. 3412 - 3419
Abstract Purpose We assessed the safety of the multikinase inhibitor regorafenib in patients with hepatocellular carcinoma (HCC) that had progressed following... 
Hematology, Oncology and Palliative Medicine | Second line | Regorafenib | Hepatocellular carcinoma | Tolerability | Safety | Receptor kinase inhibition | Safety Second line | MANAGEMENT | EFFICACY | ONCOLOGY | SUNITINIB | Carcinoma, Hepatocellular - mortality | Humans | Middle Aged | Pyridines - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Liver Neoplasms - mortality | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Time Factors | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Adult | Female | Liver Neoplasms - pathology | Antineoplastic Agents - pharmacokinetics | Phenylurea Compounds - pharmacokinetics | Liver Neoplasms - enzymology | Pyridines - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Pyridines - administration & dosage | Drug Administration Schedule | Europe | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Phenylurea Compounds - therapeutic use | Treatment Outcome | Carcinoma, Hepatocellular - enzymology | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Phenylurea Compounds - administration & dosage | Asia | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Aged | Neoplasm Staging | Care and treatment | Safety and security measures | Hepatoma | Index Medicus
Journal Article
Oncotarget, ISSN 1949-2553, 06/2019, Volume 10, Issue 40, p. 3998
Journal Article
Japanese Journal of Cancer and Chemotherapy, ISSN 0385-0684, 01/2017, Volume 44, Issue 1, pp. 47 - 51
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.